Compare Globus Medical Inc. Class A Common Stock (GMED) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B), while Direxion Daily TSLA Bull 2X Shares trades at $9.28 (market cap $3.77B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.7× Direxion Daily TSLA Bull 2X Shares's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| GMED | TSLL | |
|---|---|---|
Market Cap | $10.25B | $3.77B |
Volume | 1,059,528 | 58,292,886 |
Sector | Health | Leveraged / Inverse |
52-Week High | $96.82 | $23.03 |
52-Week Low | $58.33 | $6.74 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $10.00, down 1.48% on the day, with mixed technical signals showing a neutral overall outlook. The leveraged ETF tracks Tesla's daily performance, amplified by 2x, and benefits from recent Tesla momentum driven by Cybercab event anticipation. Key support and resistance cluster around $10-$11, with RSI indicators showing conflicting signals between short-term overbought conditions and neutral medium-term momentum.
As a leveraged ETF, TSLL carries inherent decay risks and is suitable only for short-term trading. The outlook depends entirely on Tesla's performance, with recent positive sentiment around Tesla's upcoming events providing potential upside. However, the leveraged structure makes it vulnerable to volatility decay, requiring careful risk management for investors considering exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
